胰腺癌仍然是最具侵袭性的实体瘤之一。作为一种全身性疾病，尽管多学科治疗策略不断完善，但胰腺癌的预后并未得到显着改善。对于可切除或临界可切除患者，以提高R0切除率为中心的手术策略是共识；然而，新辅助治疗在可切除患者中的作用以及化疗联合或不联合放疗的最佳新辅助治疗在临界可切除患者中存在争议。无论切缘状况如何，均建议术后接受吉西他滨/卡培他滨或 mFOLFIRINOX 辅助化疗。作为晚期或转移性患者的一线治疗策略的化疗包括 FOLFIRINOX、吉西他滨/白蛋白结合型紫杉醇或 NALIRIFOX 方案，而 5-FU 加脂质体伊立替康是唯一的二线治疗标准。免疫疗法是一种创新疗法，尽管抗 PD-1 抗体是目前唯一被批准用于治疗 MSI-H、dMMR 或 TMB 高实体瘤（仅代表胰腺癌的一小部分）的药物。增加免疫原性和克服免疫抑制肿瘤微环境的组合策略可能会使胰腺癌对免疫治疗敏感。以PARP和KRAS抑制剂为代表的靶向治疗也在研究中，显示出在提高无进展生存率和客观缓解率方面的益处。这篇综述讨论了当前的治疗方式，并重点介绍了胰腺癌的创新疗法。© 2024。作者。

Pancreatic cancer remains one of the most aggressive solid tumors. As a systemic disease, despite the improvement of multi-modality treatment strategies, the prognosis of pancreatic cancer was not improved dramatically. For resectable or borderline resectable patients, the surgical strategy centered on improving R0 resection rate is consensus; however, the role of neoadjuvant therapy in resectable patients and the optimal neoadjuvant therapy of chemotherapy with or without radiotherapy in borderline resectable patients were debated. Postoperative adjuvant chemotherapy of gemcitabine/capecitabine or mFOLFIRINOX is recommended regardless of the margin status. Chemotherapy as the first-line treatment strategy for advanced or metastatic patients included FOLFIRINOX, gemcitabine/nab-paclitaxel, or NALIRIFOX regimens whereas 5-FU plus liposomal irinotecan was the only standard of care second-line therapy. Immunotherapy is an innovative therapy although anti-PD-1 antibody is currently the only agent approved by for MSI-H, dMMR, or TMB-high solid tumors, which represent a very small subset of pancreatic cancers. Combination strategies to increase the immunogenicity and to overcome the immunosuppressive tumor microenvironment may sensitize pancreatic cancer to immunotherapy. Targeted therapies represented by PARP and KRAS inhibitors are also under investigation, showing benefits in improving progression-free survival and objective response rate. This review discusses the current treatment modalities and highlights innovative therapies for pancreatic cancer.© 2024. The Author(s).